NHS England drops cross-sex hormones for minors
Following the Cass Review, the UK's national health service is drawing further conclusions: since 9 March 2026, young people under 18 in NHS England no longer start cross-sex hormones, and the proposal is to remove these hormones permanently from the standard offering. The evidence is clear.
What NHS England is doing
- Pause since 9 March 2026: the policy introduced in March 2024, which allowed hormones from around the age of sixteen, has been suspended.
- Suspension of new prescriptions for young people under 18 until the policy is finalised.
- Mandatory reassessment of 16- and 17-year-olds who are already taking hormones. They may continue if they, their parents and their clinician record in writing that this is in their best interests.
- Proposal to stop routinely offering hormones to minors. The consultation ran from 9 March to 7 June 2026; the final policy had still not been published by October 2026.
This step follows the earlier decision by NHS England to place puberty blockers outside standard care. The broader British change of direction is described in the article on gender care in the United Kingdom. The reasoning behind both decisions is identical: there is no high-quality evidence that these interventions are safe and effective for young people under 18 in the long term.
The evidence
"The evidence on the safety, risks, benefits and outcomes of prescribing cross-sex hormones to under-18s was very limited." — NHS England
"There is insufficient evidence regarding the safety and clinical effectiveness of these hormones." — NHS England
These are not statements from a lobby group. They are formulations used by the UK's national health service, which itself implemented the policy for years. The Cass Review has swept away the scientific foundation underpinning affirmative gender care, and NHS England is now drawing the consequences step by step.
What this means for the wider debate
The international movement of reviews in the UK, Sweden, Finland and the United States is pointing in the same direction. The affirmative model that remains the norm in the Netherlands is being systematically dismantled elsewhere. Not on the basis of political preference, but on the basis of systematic reviews showing that the evidence is insufficient to justify permanent medical interventions for minors.
What this means for the Netherlands
The Amsterdam protocol, internationally known as the Dutch Protocol, served as an international standard for decades. That same protocol is now being dismantled again in the countries that adopted it. So far, Dutch gender clinics have not carried out a comparable review. This is gradually leaving the Netherlands isolated in a Western context rediscovering the value of caution. The consequences the Cass Review has had so far for Dutch healthcare, politics and the media are documented at trans-nederland.nl.
Conclusion
The NHS England review is not a temporary policy choice. It is an institutional acknowledgement that cross-sex hormones for minors do not meet the evidentiary threshold that applies to every other medical intervention. Anyone who continues to offer these interventions is no longer providing care but conducting an experiment.